SELECTED FINANCIAL STATEMENT INFORMATION (Tables)

9 Months Ended

Jul. 31, 2018

Selected Financial Statement Information [Abstract]

Schedule of Accounts Receivable [Table Text Block]

Accounts Receivable

(in thousands)	July 31, 2018			October 31, 2017
Accounts receivable		$252,885			$225,462
Less: Allowance for doubtful accounts	(3,559		)	(3,006		)
Accounts receivable, net		$249,326			$222,456

Schedule of Costs in Excess of Billings and Billings in Excess of Costs [Table Text Block]

Costs and Estimated Earnings on Uncompleted Percentage-of-Completion Contracts

(in thousands)	July 31, 2018			October 31, 2017
Costs incurred on uncompleted contracts		$33,848			$29,491
Estimated earnings	16,565			19,902
	50,413			49,393
Less: Billings to date	(37,334		)	(41,262		)
		$13,079			$8,131
Included in the accompanying Condensed Consolidated Balance Sheets under the following captions:
Accounts receivable, net (costs and estimated earnings in excess of billings)		$14,649			$9,377
Accrued expenses and other current liabilities (billings in excess of costs and estimated earnings)	(1,570		)	(1,246		)
		$13,079			$8,131

Schedule of Inventories [Table Text Block]

Inventories

(in thousands)	July 31, 2018			October 31, 2017
Finished products		$189,145			$173,559
Work in process	48,068			39,986
Materials, parts, assemblies and supplies	152,458			128,031
Contracts in process	2,171			2,415
Less: Billings to date	(54		)	(363		)
Inventories, net of valuation reserves		$391,788			$343,628

Schedule of Property, Plant and Equipment [Table Text Block]

Property, Plant and Equipment

(in thousands)	July 31, 2018			October 31, 2017
Land		$5,875			$5,435
Buildings and improvements	101,128			91,916
Machinery, equipment and tooling	222,502			191,298
Construction in progress	5,569			5,553
	335,074			294,202
Less: Accumulated depreciation and amortization	(180,460		)	(164,319		)
Property, plant and equipment, net		$154,614			$129,883

Schedule of Research and Development Expenses [Table Text Block]

The amount of new product research and development ("R&D") expenses included in cost of sales for the nine and three months ended July 31, 2018 and 2017 is as follows (in thousands):

	Nine months ended July 31,				Three months ended July 31,
	2018		2017		2018		2017
R&D expenses		$40,680		$33,889		$14,020		$11,420

Schedule of Redeemable Noncontrolling Interests [Table Text Block]

Management's estimate of the aggregate Redemption Amount of all Put Rights that the Company could be required to pay is as follows (in thousands):

	July 31, 2018		October 31, 2017
Redeemable at fair value		$84,604		$82,128
Redeemable based on a multiple of future earnings	48,995		48,995
Redeemable noncontrolling interests		$133,599		$131,123

Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]

Changes in the components of accumulated other comprehensive loss for the nine months ended July 31, 2018 are as follows (in thousands):

	Foreign Currency Translation			Pension Benefit Obligation			Accumulated Other Comprehensive Loss
Balances as of October 31, 2017		($9,533	)		($1,023	)		($10,556	)
Unrealized gain	1,137			221			1,358
Amortization of unrealized loss	—			11			11
Balances as of July 31, 2018		($8,396	)		($791	)		($9,187	)